{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:51:48Z","timestamp":1781643108959,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Molecular profiling has transformed risk stratification in myelodysplastic neoplasms (MDS). However, the independent prognostic value of specific genomic alterations beyond comprehensive molecular scoring remains unclear. We investigated whether\n                      <jats:italic>CUX1<\/jats:italic>\n                      copy-number loss (haploinsufficiency) adds prognostic value and its association with other mutations. Given its correlation with chromosome 7 abnormality, we examined its independent significance within the current MDS molecular framework.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort of 501 MDS patients with available\n                      <jats:italic>CUX1<\/jats:italic>\n                      copy-number data (CNACS gene-level calls) and complete clinical follow-up was analyzed from cBioPortal. We assessed associations with clinical characteristics, co-occurring alterations, and survival. Cox proportional hazards models evaluated independence adjusting for IPSS-R and IPSS-M.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss occurred in 129\/501 patients (26%), nearly always with \u2212\u20097\/del(7q) (98%). Patients with\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss had higher marrow blasts (median 7% vs. 4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), IPSS-R scores (6.9 vs. 4.6), and IPSS-M scores (2.33 vs. 0.79).\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss strongly associated with\n                      <jats:italic>EZH2<\/jats:italic>\n                      alterations (OR 223.8) and complex karyotype (60%). In univariable analysis,\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss predicted inferior overall survival (OS; median 11.8 vs. 27.1 months; HR 2.39, 95%CI 1.85\u20133.08,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and leukemia-free survival (LFS; HR 2.30, 95%CI 1.78\u20132.98,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). After IPSS-M adjustment, associations were non-significant (OS HR 1.27,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.11; LFS HR 1.23,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.15) with negligible incremental discrimination. Within the \u2212\u20097\/del(7q) subgroup, no survival difference was detected (OS\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.41; LFS\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.31).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss identifies high-risk MDS with \u2212\u20097\/del(7q) and\n                      <jats:italic>EZH2<\/jats:italic>\n                      co-alterations but provides no independent prognostic information beyond IPSS-M. Isolated\n                      <jats:italic>CUX1<\/jats:italic>\n                      deletions are rare.\n                      <jats:italic>CUX1<\/jats:italic>\n                      loss reflects\u2009\u2212\u20097\/del(7q) biology rather than independent prognostic significance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00277-026-06936-y","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:13:20Z","timestamp":1773386000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of CUX1 genomic deletion in myelodysplastic neoplasms"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3419-2173","authenticated-orcid":false,"given":"Mohamed M.","family":"Khamis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Babic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alkharabsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"20","key":"6936_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"12","key":"6936_CR2","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465. https:\/\/doi.org\/10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"key":"6936_CR3","doi-asserted-by":"publisher","unstructured":"Bernard E, Tuechler H, Greenberg PL et al (2022) Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 1(7). https:\/\/doi.org\/10.1056\/EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008"},{"issue":"6","key":"6936_CR4","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM et al (1997) International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood 89(6):2079\u20132088. https:\/\/doi.org\/10.1182\/blood.V89.6.2079","journal-title":"Blood"},{"issue":"1","key":"6936_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/hematology.2022000349","volume":"2022","author":"M Cazzola","year":"2022","unstructured":"Cazzola M (2022) Risk Stratifying MDS in the Time of Precision Medicine. Hematol Am Soc Hematol Educ Program 2022(1):375\u2013381. https:\/\/doi.org\/10.1182\/hematology.2022000349","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"6936_CR6","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1038\/s41375-020-0728-x","volume":"34","author":"E Cris\u00e0","year":"2020","unstructured":"Cris\u00e0 E, Kulasekararaj AG, Adema V et al (2020) Impact of Somatic Mutations in Myelodysplastic Patients With Isolated Partial or Total Loss of Chromosome 7. Leukemia 34(9):2441\u20132450. https:\/\/doi.org\/10.1038\/s41375-020-0728-x","journal-title":"Leukemia"},{"issue":"2","key":"6936_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MOH.0000000000000699","volume":"29","author":"MRM Jotte","year":"2022","unstructured":"Jotte MRM, McNerney ME (2022) The Significance of CUX1 and Chromosome 7 in Myeloid Malignancies. Curr Opin Hematol 29(2):92\u2013102. https:\/\/doi.org\/10.1097\/MOH.0000000000000699","journal-title":"Curr Opin Hematol"},{"issue":"10","key":"6936_CR8","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/s41375-023-02003-x","volume":"37","author":"M Mori","year":"2023","unstructured":"Mori M, Kubota Y, Durmaz A et al (2023) Genomics of Deletion 7 and 7q in Myeloid Neoplasm: From Pathogenic Culprits to Potential Synthetic Lethal Therapeutic Targets. Leukemia 37(10):2082\u20132093. https:\/\/doi.org\/10.1038\/s41375-023-02003-x","journal-title":"Leukemia"},{"issue":"19","key":"6936_CR9","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/onc.2014.196","volume":"34","author":"H Honda","year":"2015","unstructured":"Honda H, Nagamachi A, Inaba T (2015) \u20137\/\u20137q- Syndrome in Myeloid-Lineage Hematopoietic Malignancies: Attempts to Understand This Complex Disease Entity. Oncogene 34(19):2413\u20132425. https:\/\/doi.org\/10.1038\/onc.2014.196","journal-title":"Oncogene"},{"key":"6936_CR10","doi-asserted-by":"publisher","unstructured":"Halik A, Tilgner M, Silva P et al Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients. J Hematol Oncol, 17(1), 70. https:\/\/doi.org\/10.1186\/s13045-024-01590-1","DOI":"10.1186\/s13045-024-01590-1"},{"issue":"6","key":"6936_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1182\/blood-2012-04-426965","volume":"121","author":"ME McNerney","year":"2013","unstructured":"McNerney ME, Brown CD, Wang X et al (2013) CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 121(6):975\u2013983. https:\/\/doi.org\/10.1182\/blood-2012-04-426965","journal-title":"Blood"},{"issue":"14","key":"6936_CR12","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/bloodadvances.2018028423","volume":"3","author":"M Aly","year":"2019","unstructured":"Aly M, Ramdzan ZM, Nagata Y et al (2019) Distinct clinical and biological implications of CUX1 in myeloid neoplasms. Blood Adv 3(14):2164\u20132178. https:\/\/doi.org\/10.1182\/bloodadvances.2018028423","journal-title":"Blood Adv"},{"issue":"1","key":"6936_CR13","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-021-22750-8","volume":"12","author":"E Supper","year":"2021","unstructured":"Supper E, Rudat S, Iyer V et al (2021) Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia. Nat Commun 12(1):2482. https:\/\/doi.org\/10.1038\/s41467-021-22750-8","journal-title":"Nat Commun"},{"issue":"Supplement 1","key":"6936_CR14","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.1182\/blood-2023-189407","volume":"142","author":"I Bouligny","year":"2023","unstructured":"Bouligny I, Murray G, Ho T et al (2023) CUX1mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications. Blood 142(Supplement 1):5978\u20135979. https:\/\/doi.org\/10.1182\/blood-2023-189407","journal-title":"Blood"},{"issue":"5","key":"6936_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"},{"key":"6936_CR16","doi-asserted-by":"publisher","unstructured":"Bernard E, Nannya Y, Hasserjian RP et al Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med, 26(10), 1549\u20131556. https:\/\/doi.org\/10.1038\/s41591-020-1008-z","DOI":"10.1038\/s41591-020-1008-z"},{"issue":"4","key":"6936_CR17","doi-asserted-by":"publisher","first-page":"101054","DOI":"10.1016\/j.gim.2023.101054","volume":"26","author":"Y Akkari","year":"2024","unstructured":"Akkari Y, Baughn LB, Kim A et al (2024) ACMG Technical Laboratory Standards: Cytogenomic Studies of Acquired Chromosomal Abnormalities in Neoplastic Blood, Bone Marrow, and Lymph Nodes. Genet Med 26(4):101054. https:\/\/doi.org\/10.1016\/j.gim.2023.101054","journal-title":"Genet Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06936-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:54:39Z","timestamp":1781639679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6936"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06936-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used only de-identified, publicly available data from cBioPortal. No additional ethics approval was required, as the original source studies had obtained appropriate ethics approvals and informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}